Ozempic copies restricted after US judge denies injunction
April 24 (Reuters) - A U.S. judge on Thursday rejected a bid by compounding pharmacies to keep making copies of Novo Nordisk's (NOVOb.CO), opens new tab popular diabetes and weight-loss drugs Ozempic and Wegovy while a legal challenge over drug shortages unfolds, court records show.
The decision came in response to a February lawsuit from a compounding industry group against the U.S. Food and Drug Administration's decision that there was no longer a shortage of the medicines' active ingredient, semaglutide.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
Compounders had been allowed to produce hundreds of thousands of doses of copies of Novo's obesity and diabetes drugs only while the FDA said they were in short supply. Many of these are sold by large telehealth companies like Hims & Hers.
U.S. District Judge Mark Pittman in Texas denied compounders' bid for a preliminary injunction, according to the court docket. Pittman filed his legal reasoning under seal, but by denying the injunction request, a May timeline set by the FDA for when large U.S. compounders will have to exit the market remains in place.
It also follows a decision the judge made earlier this year refusing to allow compounding pharmacies to keep making copies of Eli Lilly's (LLY.N), opens new tab weight-loss and diabetes drugs Zepbound and Mounjaro.
The FDA and Novo Nordisk did not immediately respond to requests for comment.
Lee Rosebush, chairman of lead plaintiff Outsourcing Facilities Association, told Reuters that his organization had presented evidence of an ongoing semaglutide shortage that was obtained after the lawsuit was filed. However, Rosebush said the judge declined to consider it, finding that it was filed late.
The FDA had said it would not take any enforcement action against compounders before the court ruled.
The regulator has given larger so-called outsourcing facilities, which make compounded drugs in bulk and are regulated by the agency, until May 22. Smaller compounding pharmacies, which make drugs to fill prescriptions for individual patients and are primarily overseen by U.S. states, must immediately cease making copies of semaglutide.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
5 hours ago
- Reuters
China puts six-month limit on its ease of rare-earth export licenses, WSJ reports
June 11 (Reuters) - China is putting a six-month limit on rare-earth export licenses for U.S. automakers and manufacturers, The Wall Street Journal reported on Wednesday citing people familiar with the matter.
Reuters
5 hours ago
- Reuters
IMF, Serbia reach staff-level agreement on 36-month deal
BELGRADE, June 11 (Reuters) - The International Monetary Fund (IMF) and Serbia have reached staff-level agreement on the first review under a 36-month arrangement to help support economic reforms, the fund said in a statement on Wednesday. The so-called Policy Coordination Instrument (PCI) was signed in October to make it easier for the Balkan country to secure lending from other sources. Under the arrangement, Serbian authorities are committed to a fiscal deficit limit of 3% of gross domestic product over three years. The review will be subject to approval by the IMF Executive Board, the fund said in the statement which was issued after its two-week trip to Serbia. It also warned that downside risks for the economy were elevated. The IMF said political tensions over anti-government protests and blockades of state universities launched last November "may weigh on confidence". Serbia has seen months of anti-government rallies after 16 deaths from a railway station roof collapse triggered accusations of widespread corruption and negligence. The IMF warned that a global growth slowdown and increasing "geoeconomic fragmentation could negatively affect exports and foreign direct investment". However, it expects Serbia's economy to grow 3% this year and 4% in 2026. "Serbia has built up substantial buffers to respond to shocks — foreign exchange reserves and government deposits are high, public debt is declining, and banks are well-capitalised and liquid," the IMF said.
Reuters
5 hours ago
- Reuters
Lutnick says US tariff levels on China won't change
June 11 (Reuters) - U.S. Commerce Secretary Howard Lutnick said on Wednesday that the 55% tariffs imposed by the United States on China will not change after a trade deal was struck between the two countries. A U.S.-China trade deal is "done," U.S. President Donald Trump said earlier in the day, hours after negotiators from Washington and Beijing agreed on a framework to get a fragile trade truce back on track. "You can definitely say that," Lutnick told CNBC in an interview when asked if the tariff levels on China would not change. The trade deal, which needs to signed by both Trump and Chinese President Xi Jinping, would remove Chinese export restrictions on rare earth minerals and other critical industrial components. Lutnick also said China has agreed to examine how it can do more business with the U.S. He said that trade deals with other countries can be expected starting next week.
